6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
18m ago	Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
18m ago	Surface Transforms plc – in Administration, Sale of Business and Assets
19m ago	Guerbet: Changes to the Composition of Guerbet’s Board of Directors.
19m ago	RENAULT S.A. : disclosure of trading in own shares from May 15 to May 20, 2026
19m ago	Assystem: Combined General Meeting of 22 May 2026 - Voting Results and dividend for financial year 2025

About

158.65CHF-0.15 -0.09%

Closed • Updated at 16:53 GMT+00:00

Market Cap$47.39B

P/E Ratio74.85

Volume273.6K

Beta0.33

RSI49.80

Gross Margin68.67%

Health TechnologyPharmaceuticals: Major

Galderma Group Ag — investor relations, events, news, and company updates on 6ix.

Latest News

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency

Galderma Shareholders Approve All Annual General Meeting Proposals

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

Community Chat

Ask AI